Our data suggest that patients with high FAM210B expression might exhibit resistance to sunitinib but could benefit more from immunotherapy, implicating FAM210B as a potential biomarker for tailoring HCC treatment strategies. This evidence concerns the gene MIMS2 and hepatocellular carcinoma.